Vanguard Global Advisers
CAI

Vanguard Global Advisers’s Caris Life Sciences CAI Stock Holding History

Vanguard Global Advisers’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.3K Buy
635
+110
+21% +$1.97K ﹤0.01% 3457
2026
Q1 		$9.39K Buy
+525
New +$11.5K ﹤0.01% 3486

Other funds holding CAI

JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $27.2B AUM 43.16% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Global Advisers's CAI Position: Q2 2026 in Review

Vanguard Global Advisers increased its Caris Life Sciences (CAI) stake by 21% in Q2 2026, buying an estimated $1.97K and bringing the position to 635 shares worth $11.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3457.

Vanguard Global Advisers first reported a position in CAI in Q1 2026 and has held it in 2 quarters since. 228 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Vanguard Global Advisers held 635 shares of Caris Life Sciences worth $11.3K as of Q2 2026.
  • Vanguard Global Advisers bought 110 Caris Life Sciences shares in Q2 2026, an estimated $1.97K.
  • Caris Life Sciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3457 holding.
  • Vanguard Global Advisers first reported a position in Caris Life Sciences in Q1 2026 and has held it in 2 quarters since.
  • 228 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.